Kratom use during pregnancy carries real risks for both the mother and the baby, with the most consistently documented outcome being neonatal withdrawal. Every published case report to date has described withdrawal symptoms in the newborn, sometimes severe enough to require weeks of treatment with morphine and other medications. The evidence base is still small, built mostly on case reports rather than large studies, but what exists paints a consistent and concerning picture. Because kratom is sold as an herbal supplement and flies under the radar of standard hospital drug screens, the problem is almost certainly underrecognized.
How Kratom Reaches the Fetus
Kratom’s primary active compounds act on opioid receptors in the brain. That matters during pregnancy because substances with opioid-like activity are well known to cross the placenta. A review of new psychoactive substances and pregnancy confirmed that many of these compounds, including kratom alkaloids, can reach the fetus through the placenta and can also be secreted into breast milk.1Current Pharmacology Reports. A Review on the Potential Health Concerns of New Psychoactive Substances on Pregnancy and Lactation: An Overlooked Threat Once these compounds cross to the fetal side, the developing baby is exposed to their effects throughout the pregnancy. If the mother uses kratom regularly, the fetus develops a physical dependence of its own, setting up the withdrawal that comes after delivery when the supply is suddenly cut off.
Animal and laboratory research adds another layer of concern. A study using zebrafish embryos exposed to kratom leaf extracts found concentration-dependent lethality and developmental abnormalities. The extracts affected hatchability, eye size, heartbeat, and body length, with more concentrated preparations causing more severe damage.2PubMed. Toxicity assessment of Mitragyna speciosa leaf extracts using zebrafish (Danio rerio) embryos and analysis of their Q-TOF LCMS chemical profiles Zebrafish are not humans, and doses in laboratory dishes do not translate directly to what a pregnant person swallows. But these findings suggest the compounds in kratom have the biological potential to disrupt embryonic development, which is consistent with what clinicians have observed in human newborns.
Neonatal Withdrawal Is the Headline Risk
The most thoroughly documented consequence of prenatal kratom exposure is neonatal abstinence syndrome, or NAS. This is the same type of withdrawal that occurs in babies born to mothers who used prescription opioids or heroin during pregnancy. A systematic review that gathered all available peer-reviewed evidence on kratom and pregnancy outcomes analyzed six case reports and found that every single case involved withdrawal symptoms in the newborn, and every one required medication to manage.3PubMed Central. Outcomes of mothers and newborns to prenatal exposure to kratom: a systematic review Six cases is a tiny number in medical research, but the consistency is notable: there were no exceptions.
What does that withdrawal look like in practice? One published case described a full-term baby born to a mother who used kratom chronically throughout her pregnancy. The infant developed withdrawal symptoms and needed regular doses of oral morphine that were gradually reduced over 37 days, along with another medication called clonidine to help manage symptoms. The baby was not discharged from the hospital until day 41 of life, well over a month after birth.4PubMed Central. Novel case of maternal and neonatal kratom dependence and withdrawal That is a significant hospitalization for a newborn and a difficult experience for any family. Another case report described a term neonate who similarly required opiate treatment for drug withdrawal after being born to a chronic kratom user.5PubMed Central. Natural drugs, not so natural effects: Neonatal abstinence syndrome secondary to ‘kratom’
Withdrawal symptoms in newborns typically include excessive crying, tremors, poor feeding, irritability, sleep difficulties, and sometimes seizures. These are the same symptoms seen with opioid-related NAS, which makes sense given kratom’s activity at opioid receptors. Mothers in reported cases also experienced withdrawal symptoms themselves, meaning both the mother and infant often needed treatment simultaneously.3PubMed Central. Outcomes of mothers and newborns to prenatal exposure to kratom: a systematic review
Birth Weight and Growth Concerns
Beyond withdrawal, there are signs that kratom exposure during pregnancy may affect fetal growth. A literature review that compiled birth data on ten neonates exposed to kratom before birth found that while all were born at term and had normal Apgar scores (meaning they appeared generally healthy at birth), at least a quarter of them were small for gestational age. That is a clinical way of saying they weighed less than expected for how far along the pregnancy was, which suggests possible intrauterine growth restriction.6Research and Reports in Neonatology. Antenatal Kratom Exposure: Literature Review and Clinical Management Recommendations No neonatal deaths were reported in any of the cases.
The good news in those numbers, such as it is, is that babies exposed to kratom prenatally have generally survived and been delivered at full term. The picture is not one of catastrophic outcomes at birth. But the growth restriction signal is worth paying attention to, because being born small for gestational age can carry its own health consequences for the child later on, including metabolic and developmental issues. With only ten cases on record, it is impossible to say whether this is a reliable pattern or a statistical quirk of small numbers. The evidence is thin enough that clinicians are working with educated guesses rather than firm data.
Why Standard Drug Screens Miss Kratom
One of the biggest clinical challenges with kratom and pregnancy is that hospitals usually cannot detect it. Standard urine toxicology screens that are routinely used in labor and delivery settings test for opioids, amphetamines, cocaine, cannabis, and a few other common substances. Kratom does not show up on these panels. Its active compounds are chemically distinct enough from traditional opioids that they slip through undetected.5PubMed Central. Natural drugs, not so natural effects: Neonatal abstinence syndrome secondary to ‘kratom’ Specialized testing exists but is not standard, and most hospitals do not have it readily available.
This matters because if a baby develops withdrawal symptoms and the mother’s drug screen comes back clean, clinicians can be caught off guard. They may not immediately recognize the cause, which delays appropriate treatment. Lack of disclosure by people using kratom and the limited laboratory testing options together create a significant blind spot for healthcare providers and public health efforts.3PubMed Central. Outcomes of mothers and newborns to prenatal exposure to kratom: a systematic review In the published case reports, diagnosis often depended entirely on the mother volunteering the information about her kratom use, sometimes only after other substances had already been ruled out.
If you are using kratom and become pregnant or are planning a pregnancy, telling your healthcare provider is one of the most important things you can do. Not because you will be judged (though fear of judgment is understandable), but because medical teams cannot plan for a baby’s withdrawal if they do not know it is coming. Early awareness gives the neonatal team time to prepare and can shorten the baby’s hospital stay.
Why Some Pregnant People Turn to Kratom
Understanding why someone would use kratom during pregnancy helps put the risks in context. Kratom is widely marketed online and in retail settings as a natural alternative for pain, anxiety, depression, and opioid withdrawal. That marketing has contributed to rising use in the general population, including among pregnant people.3PubMed Central. Outcomes of mothers and newborns to prenatal exposure to kratom: a systematic review People seeking relief from chronic pain or trying to stop using stronger opioids may see kratom as a safer, more “natural” option, especially since it is legal in most U.S. states and available without a prescription.
A survey of pregnant and lactating individuals with substance use disorders sheds some light on this. Among the respondents, about a third reported having used kratom at some point, and those who used it cited relieving opioid withdrawal symptoms as a primary reason. Others mentioned pain control, relaxation, and stress relief.7Journal of Addiction Medicine. Kratom Use Among Pregnant and Lactating Individuals With Substance Use Disorder The percentage who used kratom specifically during pregnancy was much smaller, at about 5% of the surveyed group, but even that number is significant when scaled to the broader population of pregnant people dealing with opioid use disorder.
The difficult reality is that for someone struggling with opioid dependence, the alternative to kratom is not necessarily “no drug at all.” It may be heroin or fentanyl, which carry far higher overdose and contamination risks. Medical providers generally recommend medication-assisted treatment with buprenorphine or methadone for pregnant people with opioid dependence, since these have been studied much more extensively in pregnancy and have established protocols for managing neonatal outcomes. Kratom, by contrast, has no standardized dosing, no quality control requirements, and no clinical guidelines for use in pregnancy. The “natural” label makes it feel safer, but the evidence does not support that perception.
Kratom and Breastfeeding
Information about kratom and breastfeeding is even thinner than the pregnancy data. The same review of new psychoactive substances that confirmed placental transfer also noted that many of these compounds can be secreted into breast milk, potentially causing adverse effects in nursing infants including intoxication.1Current Pharmacology Reports. A Review on the Potential Health Concerns of New Psychoactive Substances on Pregnancy and Lactation: An Overlooked Threat However, the review also acknowledged that there is very limited information on how much of these substances actually transfers into breast milk or what concentrations reach the infant. Clinical trials focusing on pregnant and lactating individuals are essentially nonexistent for kratom.
In the survey of individuals with substance use disorders, only one respondent reported using kratom during lactation.7Journal of Addiction Medicine. Kratom Use Among Pregnant and Lactating Individuals With Substance Use Disorder That single data point tells us almost nothing about safety. Given that kratom’s active compounds act on the same receptors as opioids and that opioids are known to pass into breast milk in meaningful amounts, most clinicians would advise caution. But the honest answer is that nobody can tell you exactly how much kratom makes it into breast milk or what effect it has on a nursing infant, because that research has not been done.
The “Natural” Misconception
Kratom’s status as an herbal product creates a particular kind of risk during pregnancy. Many people equate “natural” and “herbal” with “safe,” and this belief can be reinforced by the way kratom is sold. It appears alongside other herbal supplements in smoke shops and online stores, often with marketing language that emphasizes its plant origins and traditional use in Southeast Asia. None of that packaging carries the warnings about pregnancy that would be required on an FDA-approved medication.
The FDA does not regulate kratom as a pharmaceutical. It has not been approved for any medical use, and the agency has issued warnings about its safety profile. But because it sits in a regulatory gray area as a supplement, there are no dosing guidelines, no purity standards, and no required pregnancy warnings on the label. A person buying kratom capsules at a convenience store would have no way of knowing from the packaging that the product could cause their baby to spend six weeks in a hospital going through withdrawal. The disconnect between how kratom is presented to consumers and what the medical case reports actually show is striking.
Complicating things further, kratom products vary enormously in potency. Different strains, different vendors, and different batches can contain very different concentrations of the active compounds. This means that even if someone had been using kratom before pregnancy without obvious problems, they have no reliable way to know what dose they are actually taking or how a change in product might affect their developing baby. The lack of standardization is a problem for anyone using kratom, but the stakes are uniquely high during pregnancy.
What Happens If You Stop Kratom During Pregnancy
If you discover you are pregnant while using kratom regularly, the question of whether to stop abruptly is not straightforward. Sudden cessation of any opioid-like substance during pregnancy can trigger withdrawal in the mother, and maternal withdrawal itself can be harmful to the fetus. Stress hormones surge, blood pressure can spike, and in severe cases the physiological stress can contribute to premature labor or other complications.
This is the same dilemma faced by pregnant people who are dependent on prescription opioids, and it is why medical guidelines for opioid dependence in pregnancy generally recommend a supervised taper or transition to medication-assisted treatment rather than abrupt discontinuation. Because kratom acts on the same receptor pathways, the same logic applies in principle, even though there are no formal clinical guidelines specifically for kratom cessation during pregnancy. The safest approach is to work with a healthcare provider who can help manage withdrawal symptoms and monitor both the mother and the fetus during the process.
The published case reports make clear that the mothers in these situations also experienced withdrawal, reinforcing that kratom dependence is a genuine physiological phenomenon, not merely a habit.3PubMed Central. Outcomes of mothers and newborns to prenatal exposure to kratom: a systematic review This is worth emphasizing because one of the myths around kratom is that it is not truly addictive. Regular use clearly produces physical dependence, and the withdrawal, for both mother and baby, requires medical management.
Why the Research Is So Limited
You may have noticed that the numbers in this article are small: six case reports in one review, ten neonates in another. That is not because the article is cherry-picking. It is because the entire published medical literature on kratom and pregnancy is that small. Researchers have acknowledged this gap repeatedly, but several factors keep the evidence base from growing quickly.
For one, clinical trials involving pregnant people and a substance with known risks would be unethical to design. You cannot randomize pregnant volunteers into a “take kratom” group and a “don’t take kratom” group. So research depends on observational data, case reports, and surveys, all of which come with limitations. The diagnostic blind spot created by inadequate drug screening means many cases of prenatal kratom exposure likely go unidentified and unreported.5PubMed Central. Natural drugs, not so natural effects: Neonatal abstinence syndrome secondary to ‘kratom’ If the hospital does not test for it and the mother does not disclose it, the case never enters the medical record as kratom-related.
Stigma is another barrier. People who use substances during pregnancy face significant social and sometimes legal consequences, which discourages honest disclosure to healthcare providers. A case review noted that lack of disclosure by kratom users is one of the major challenges facing both clinicians and public health surveillance of the problem.3PubMed Central. Outcomes of mothers and newborns to prenatal exposure to kratom: a systematic review The result is a cycle: limited reporting leads to limited awareness, which leads to limited screening, which leads to even less reporting. Breaking that cycle probably requires both better testing technology and a clinical culture where pregnant patients feel safe being truthful about what they are taking.
Long-Term Outcomes for Exposed Children
One of the most important questions a parent would ask, what happens to these children as they grow up, is unfortunately unanswerable right now. The published case reports follow infants through their initial hospitalization and discharge, but there are no published studies tracking the developmental outcomes of kratom-exposed children into toddlerhood, school age, or beyond. The literature review that examined ten neonates reported no deaths and generally reassuring immediate birth parameters like normal Apgar scores and term delivery.6Research and Reports in Neonatology. Antenatal Kratom Exposure: Literature Review and Clinical Management Recommendations But surviving the newborn period and thriving in the long run are different questions.
Research on other opioid-exposed newborns (those exposed to prescription opioids, heroin, or medication-assisted treatments like methadone) does offer some indirect guidance. That literature suggests a range of outcomes, from children who develop typically to those who show subtle cognitive, behavioral, or motor differences. Whether kratom exposure carries the same profile, a worse one, or a milder one is genuinely unknown. The zebrafish embryo data, with its findings of developmental defects at higher concentrations, raises the possibility that kratom’s effects on development could go beyond simple withdrawal. But translating fish laboratory results to human babies involves enormous uncertainty, and it would be irresponsible to draw firm conclusions from them. What can be said is that this is an area where the absence of evidence is not evidence of safety.